Supplementary file 1. Risk of drug failure of different bDMARDs monotherapy before and after 31st december 2009.

bDMARD monotherapy	***Adjusted HR (95%CI) before 31st december 2009***	***p***	***Adjusted HR (95%CI) after 1st January 2010***	***p***
ETA monotherapy (385 patients)	1 (ref)		1 (ref)	
ADA monotherapy (201 patients)	1.40 (1.09 – 1.78)	0.008	1.17 (0.70-1.96)	0.554
INF monotherapy (81 patients)	2.20 (1.59 – 3.05)	<0.001	2.72 (1.51 – 4.90)	0.001
GOL monotherapy (21 patients)	*Not applicable**		1.38 (0.60 – 3.18)	0.447
CTZ monotherapy (30 patients)	*Not applicable**		1.08 (0.51 – 2.29)	0.843
ABA monotherapy (34 patients)	*Not applicable**		0.46 (0.18 – 1.15)	0.097
TCZ monotherapy (47 patients)	*Not applicable**		0.82 (0.45 – 1.48)	0.504

** Not applicable: based on the changes occurred in local approved first-line bDMARD deliverability.*